Top Medical News
2 hours ago
It appears that the use of bioresorbable vascular scaffolds (BVS) in patients undergoing percutaneous coronary intervention is linked to higher thrombotic risk and reduced efficacy over time compared with metallic everolimus-eluting stents (EES), a recent study suggests.
3 hours ago
The risk of cardiovascular morbidity is reduced in elderly patients who highly adhere to antihypertensive drug therapy, reports a new study. Furthermore, adherence to antihypertensives also lowers the risk of heart failure and stroke, but not myocardial infarction (MI), and extending to all-cause death.
20 hours ago
Occasional and weekly chest pain and shortness of breath during activity in patients with cardiovascular disease (CVD) appear to be associated with several modifiable patient characteristics such as weight, psychological health and number of other painful body sites, a study has shown.
Roshini Claire Anthony, Yesterday

Insulin degludec had comparable cardiovascular safety and reduced the risk of severe hypoglycaemia compared with insulin glargine U100 in patients with type 2 diabetes and high cardiovascular risk, according to results of the DEVOTE* study.

Yesterday
Glycated haemoglobin (HbA1c) is a predictor of major adverse cardiac events (MACEs) in nondiabetic individuals after acute myocardial infarction (AMI), a new retrospective observational study reports.
Yesterday
Podcast: Dr Steven Marso speaks about the cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes with high cardiovascular risk.
Yesterday
Podcast: Professor Robert Henry talks about the effects of alirocumab vs usual care in patients with type 2 diabetes and mixed dyslipidemia.
Special Reports
25 May 2017
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
24 Apr 2017
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat pain and inflammation in patients with arthritis, but the vascular effects of some NSAIDs have cast doubt on whether they can be used in patients at risk for cardiovascular (CV) disease. At the American Heart Association’s Scientific Sessions 2016 held recently in New Orleans, Louisiana, US, Professor Steven Nissen of the Cleveland Clinic in Cleveland, Ohio, US, presented latest data from the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen) trial that evaluated the CV risk and safety profile of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib vs nonselective NSAIDs.
16 Mar 2017
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.
07 Mar 2017
At the 17th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.
16 Feb 2017
At the recent launch of an exclusive guidebook on vasodilating β-blockers for the treatment of hypertension and chronic heart failure (HF), Professor Athanasios J. Manolis delivered a lecture on why nebivolol is different from the other agents in its class.
16 Dec 2016
During the 8th Diabetes Complications Conference & Grand Rounds 2016, Dr Azani Mohamed Daud talked about the guidelines on the use of ACEIs and ARBs in hypertension, and highlighted their clinical efficacies for hypertension treatment.
Prof. Abdul Rashid, Prof. Martin Strauss, Prof. Alistair Hall, 12 Dec 2016
Hypertension is a leading cause of mortality globally and is of particular concern in the Asia Pacific region where there are more deaths due to poor blood pressure (BP) control than in any other region in the world. At a recent Servier-sponsored satellite symposium held during the ASEAN Federation of Cardiology Congress in Yangon, Myanmar, Professor Abdul Rashid, An Nur Specialist Hospital, Selangor, Malaysia, discussed the challenges associated with managing hypertension in the region. In addition, Professor Martin Strauss, North York General Hospital, Toronto, Canada and Professor Alistair Hall, Leeds General Infirmary, UK, discussed the different effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) on cardiovascular (CV) outcomes, highlighting the additional protection against myocardial infarction (MI) offered by ACE inhibitors such as perindopril.
Conference Reports
Roshini Claire Anthony, 21 Jun 2017

Insulin degludec had comparable cardiovascular safety and reduced the risk of severe hypoglycaemia compared with insulin glargine U100 in patients with type 2 diabetes and high cardiovascular risk, according to results of the DEVOTE* study.

21 Jun 2017
Podcast: Dr Steven Marso speaks about the cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes with high cardiovascular risk.
21 Jun 2017
Podcast: Professor Robert Henry talks about the effects of alirocumab vs usual care in patients with type 2 diabetes and mixed dyslipidemia.
21 Jun 2017
Podcast: Professor Bruce Neal summarizes the key findings of the Canagliflozin Cardiovascular Assessment Study.
21 Jun 2017
Podcast: Dr Carla Greenbaum speaks about the potential clinical impact of identifying individuals at risk of type 1 diabetes.
Audrey Abella, 16 Jun 2017
Sodium-glucose transporter-2 inhibitors (SGLT-2i) were associated with a significant reduction in the rates of death and hospitalization due to heart failure (HF) in patients with type 2 diabetes (T2D) regardless of pre-existing cardiovascular disease (CVD), according to a new analysis of the CVD-REAL* study presented at the American Diabetes Association’s 77th Scientific Sessions held in San Diego, California, US.
Roshini Claire Anthony, 14 Jun 2017

The sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin was associated with better cardiovascular (CV) outcomes compared with placebo in individuals with type 2 diabetes and high CV risk, though it was also linked to an elevated risk of amputation, according to findings from the CANVAS* Program.

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD